Steven Goldman, M.D., holds the C. Leonard Pfeiffer Endowed Chair in Cardiovascular Medicine at the UA Sarver Heart Center, University of Arizona.
Dr. Goldman has won numerous awards for teaching over the years. In 2008, Dr. Goldman was named the Founders Day Speaker at the University of Arizona College of Medicine – Tucson. This award is given each year to a faculty member with a long successful research career at the University of Arizona. His research laboratory has received funding from the University of Arizona, Sarver Heart Center, Tech Launch Arizona, Veterans Affairs, National Institutes of Health, American Heart Association, Arizona Biomedical Research Commission, the biotechnology industry and private foundations. His laboratory has supported the development of several young investigators, including high school students, undergraduate students, medical students, house staff, PhD, and MD investigators.
A native of Ohio, he received his undergraduate education at Cornell University and his medical doctorate from The University of Cincinnati. His residency training was at The University of Illinois, The University of Chicago, and Stanford University. He received his cardiology training at the Pacific Medical Center in San Francisco, California. Dr. Goldman is a Vietnam veteran, having served as a Navy Physician assigned to the Marine Corp in Danang in 1970-71. He came to The University of Arizona in 1975 and was Chief of Cardiology at the Southern Arizona VA Health System for over 35 years.
Dr. Goldman and Dr. Jordan Lancaster co-founded Avery Therapeutics in 2016 to develop new treatments for heart failure. The laboratory work that formed the foundation of Avery Therapeutics was done in Dr. Goldman’s laboratory at the Southern Arizona VA Health Care Center and the University of Arizona. Dr. Goldman’s laboratory is currently focusing on developing immunomodulatory biologic therapeutics to treat heart disease.
Dr. Goldman’s clinical research has focused on graft patency (evaluating the openness of arteries) after coronary artery bypass grafting (CABG). He has been the principle investigator and co-investigator on a number of large VA multicenter studies that defined the appropriate use of aspirin for vein graft patency after CABG. He is currently completing a long-term trial defining radial artery graft patency after CABG.
Dr. Goldman’s work in the laboratory focuses on cardiovascular physiology and pharmacology. To this end, he has been investigating cell-based therapy for heart failure using stem cells seeded on a biodegradable patch as treatment for heart failure. He and Jordan Lancaster, PhD, founded Avery Therapeutics, a biotechnology start-up company that is a spin off from the University of Arizona to commercialize this idea.